Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13417273 | 0.77 | LMNA (0.55) | KDM4EALDH1A1RAB9ALMNATSHR | |
| SCHEMBL3372555 | 0.77 | LMNA (0.53) | KDM4EALDH1A1RAB9ALMNATSHR | |
| SCHEMBL13417154 | 0.76 | LMNA (0.52) | KDM4EALDH1A1RAB9ALMNATSHR | |
| SCHEMBL370114 | 0.74 | RAB9A (0.41) | KDM4EALDH1A1RAB9ALMNATSHR | |
| SCHEMBL3370616 | 0.74 | RAB9A (0.41) | KDM4EALDH1A1RAB9ALMNATSHR | |
| SCHEMBL367506 | 0.68 | TSHR (0.43) | KDM4EALDH1A1RAB9ALMNATSHR | |
| SCHEMBL1055360 | 0.66 | LMNA (0.51) | KDM4EALDH1A1RAB9ALMNATSHR | |
| SCHEMBL1988320 | 0.65 | ALDH1A1 (0.66) | KDM4EALDH1A1RAB9ATSHRGSK3A | |
| SCHEMBL19913890 | 0.65 | SMN1; SMN2 (0.36) | KDM4EALDH1A1RAB9ANLRP3 | |
| SCHEMBL9946564 | 0.64 | RAB9A (0.50) | KDM4EALDH1A1RAB9ATSHRAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312945-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | KDM4E 4506/4885ALDH1A1 851/4885RAB9A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.